

Fredrik Hieronymus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7626844/publications.pdf>

Version: 2024-02-01

31
papers

556
citations

840585

11
h-index

642610

23
g-index

35
all docs

35
docs citations

35
times ranked

861
citing authors

#	ARTICLE	IF	CITATIONS
1	Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. <i>Molecular Psychiatry</i> , 2016, 21, 523-530.	4.1	144
2	A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. <i>Translational Psychiatry</i> , 2016, 6, e834-e834.	2.4	75
3	Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis. <i>Lancet Psychiatry</i> , 2019, 6, 745-752.	3.7	50
4	The efficacy of repetitive transcranial magnetic stimulation (rTMS) for bipolar depression: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2021, 279, 250-255.	2.0	48
5	Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression. <i>Molecular Psychiatry</i> , 2018, 23, 1731-1736.	4.1	31
6	Effects of selective serotonin reuptake inhibitors on rating-scale-assessed suicidality in adults with depression. <i>British Journal of Psychiatry</i> , 2018, 212, 148-154.	1.7	23
7	Item-based analysis of the effects of duloxetine in depression: a patient-level post hoc study. <i>Neuropsychopharmacology</i> , 2020, 45, 553-560.	2.8	22
8	One (effect) size does not fit at all: Interpreting clinical significance and effect sizes in depression treatment trials. <i>Journal of Psychopharmacology</i> , 2020, 34, 1074-1078.	2.0	22
9	Optimizing psychiatric care during the COVID-19 pandemic. <i>Acta Psychiatrica Scandinavica</i> , 2020, 142, 70-71.	2.2	20
10	The efficacy of transcranial magnetic stimulation (TMS) for negative symptoms in schizophrenia: a systematic review and meta-analysis. <i>NPJ Schizophrenia</i> , 2022, 8, .	2.0	17
11	Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression. <i>Acta Psychiatrica Scandinavica</i> , 2017, 136, 343-351.	2.2	16
12	Pre-diagnostic and post-diagnostic psychopharmacological treatment of 16288 patients with bipolar disorder. <i>Bipolar Disorders</i> , 2021, 23, 357-367.	1.1	15
13	Do side effects of antidepressants impact efficacy estimates based on the Hamilton Depression Rating Scale? A pooled patient-level analysis. <i>Translational Psychiatry</i> , 2021, 11, 249.	2.4	11
14	On the Application of Machine Learning Techniques to Regression Problems in Sea Level Studies. <i>Journal of Atmospheric and Oceanic Technology</i> , 2019, 36, 1889-1902.	0.5	10
15	Multiple possible inaccuracies cast doubt on a recent report suggesting selective serotonin reuptake inhibitors to be toxic and ineffective. <i>Acta Neuropsychiatrica</i> , 2018, 30, 244-250.	1.0	9
16	The alleged lack of efficacy of antidepressants in non-severe depression: a myth debunked. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 447-449.	2.2	6
17	Low SSRI dosing in clinical practice—a register-based longitudinal study. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 434-443.	2.2	6
18	Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis. <i>NPJ Schizophrenia</i> , 2021, 7, 41.	2.0	6

#	ARTICLE	IF	CITATIONS
19	Individual variability in treatment response to antidepressants in major depression: comparing trial-level and patient-level analyses. <i>Acta Psychiatrica Scandinavica</i> , 2020, 142, 443-445.	2.2	5
20	Rating, berating or overrating antidepressant efficacy? The case of the Hamilton depression rating scale. <i>European Neuropsychopharmacology</i> , 2021, 52, 12-14.	0.3	4
21	Clinical response to <scp>SSRIs</scp> relative to cognitive behavioral therapy in depression: a symptom-specific approach. <i>World Psychiatry</i> , 2022, 21, 152-153.	4.8	4
22	Inclusion of Flexible-Dose Trials in the Meta-Analysis of SSRI Dose-Dependency. <i>American Journal of Psychiatry</i> , 2016, 173, 836-836.	4.0	3
23	Which antidepressant doses are optimal?. <i>Lancet Psychiatry</i> , 2019, 6, 552-554.	3.7	3
24	Determining maximal achievable effect sizes of antidepressant therapies in placebo-controlled trials. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 300-309.	2.2	2
25	Katakam and co-workers have not shown SSRIs to be harmful and ineffective and should stop claiming that they have. <i>Acta Neuropsychiatrica</i> , 2018, 30, 266-274.	1.0	1
26	Acoustic white noise ameliorates reduced regional brain expression of CaMKII and FosB in the spontaneously hypertensive rat model of ADHD. <i>IBRO Reports</i> , 2019, 6, 31-39.	0.3	1
27	Study 329 suggests paroxetine to exert an antidepressant effect in children and adolescents. <i>European Neuropsychopharmacology</i> , 2017, 27, S1114-S1115.	0.3	0
28	How do we determine whether antidepressants are useful or not? – Authors' reply. <i>Lancet Psychiatry</i> , 2019, 6, 888-889.	3.7	0
29	Good news regarding SSRI safety in Danish meta-analysis. <i>Acta Neuropsychiatrica</i> , 2020, 32, 54-56.	1.0	0
30	P.0452 Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: A pooled participant-level analysis. <i>European Neuropsychopharmacology</i> , 2021, 53, S330-S331.	0.3	0
31	Impact of chosen cutoff on response rate differences between selective serotonin reuptake inhibitors and placebo. <i>Translational Psychiatry</i> , 2022, 12, 160.	2.4	0